JP2023549055A5 - - Google Patents

Info

Publication number
JP2023549055A5
JP2023549055A5 JP2023524901A JP2023524901A JP2023549055A5 JP 2023549055 A5 JP2023549055 A5 JP 2023549055A5 JP 2023524901 A JP2023524901 A JP 2023524901A JP 2023524901 A JP2023524901 A JP 2023524901A JP 2023549055 A5 JP2023549055 A5 JP 2023549055A5
Authority
JP
Japan
Prior art keywords
diazaspiro
octan
amino
cancer
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023524901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549055A (ja
JP7860103B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056702 external-priority patent/WO2022093856A1/en
Publication of JP2023549055A publication Critical patent/JP2023549055A/ja
Publication of JP2023549055A5 publication Critical patent/JP2023549055A5/ja
Application granted granted Critical
Publication of JP7860103B2 publication Critical patent/JP7860103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023524901A 2020-10-27 2021-10-26 複素環式スピロ化合物及びその使用方法 Active JP7860103B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/123913 2020-10-27
CN2020123913 2020-10-27
PCT/US2021/056702 WO2022093856A1 (en) 2020-10-27 2021-10-26 Heterocyclic spiro compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2023549055A JP2023549055A (ja) 2023-11-22
JP2023549055A5 true JP2023549055A5 (cg-RX-API-DMAC7.html) 2024-11-05
JP7860103B2 JP7860103B2 (ja) 2026-05-15

Family

ID=78650109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524901A Active JP7860103B2 (ja) 2020-10-27 2021-10-26 複素環式スピロ化合物及びその使用方法

Country Status (7)

Country Link
US (1) US20230406860A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237086A1 (cg-RX-API-DMAC7.html)
JP (1) JP7860103B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021370660A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199082A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023004802A (cg-RX-API-DMAC7.html)
WO (1) WO2022093856A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
CA3227138A1 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
AR128211A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
AR128212A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
CN117186107A (zh) * 2022-05-31 2023-12-08 成都先导药物开发股份有限公司 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080540A1 (es) 2006-08-10 2008-06-08 Glaxo Group Ltd Compuestos 4-fenil-2-piridinil-metil sustituidos como moduladores de los canales de sodio con apertura por voltaje
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
AU2016245864C1 (en) * 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112021001709A2 (pt) * 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
EP3887373A1 (en) 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
AU2019404576B2 (en) 2018-12-20 2025-07-17 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors

Similar Documents

Publication Publication Date Title
JP7860103B2 (ja) 複素環式スピロ化合物及びその使用方法
US20240059703A1 (en) Heterocyclic spiro compounds and methods of use
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2022536419A5 (cg-RX-API-DMAC7.html)
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
RU2016111675A (ru) Соединения биарилацетамида и способы их применения
ES2271221T3 (es) Derivados imidazo-pirimidina como ligandos para receptores gaba.
JP2020527174A5 (cg-RX-API-DMAC7.html)
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
JP2013523884A5 (cg-RX-API-DMAC7.html)
JP2016537384A5 (cg-RX-API-DMAC7.html)
RU2017121278A (ru) Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы
NZ586579A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
HRP20151398T1 (hr) Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze
RU2007119449A (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
RU2007134899A (ru) ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGLuR2
JP2022502490A5 (cg-RX-API-DMAC7.html)
JP2018529731A5 (cg-RX-API-DMAC7.html)
RU2018112230A (ru) Бициклические соединения в качестве ингибиторов atx
JP2016504363A5 (cg-RX-API-DMAC7.html)
AU2006320480A1 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
HRP20211483T1 (hr) Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka
JP2021512954A5 (cg-RX-API-DMAC7.html)
HRP20121022T1 (hr) Kondenzirani bicikliäśki pirimidini
JP2021501806A5 (cg-RX-API-DMAC7.html)